<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Clinical   Health and Educational Psych</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/B353C72E-60A1-419D-9AF5-A8DBF60C7D77"><gtr:id>B353C72E-60A1-419D-9AF5-A8DBF60C7D77</gtr:id><gtr:firstName>Celia</gtr:firstName><gtr:surname>Morgan</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/BEDA41E9-DB2B-47F2-88D5-BAB4A38D2757"><gtr:id>BEDA41E9-DB2B-47F2-88D5-BAB4A38D2757</gtr:id><gtr:firstName>Helen</gtr:firstName><gtr:otherNames>Valerie</gtr:otherNames><gtr:surname>Curran</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0800268"><gtr:id>A6F45EF7-72CF-4CE3-A547-8A3938B13DB3</gtr:id><gtr:title>What determines an individual's vulnerability to the harmful effects of cannabis?</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0800268</gtr:grantReference><gtr:abstractText>A young person who has ever used cannabis has a 40% increased risk of developing a psychotic disorder like schizophrenia; in those using heavily, the increased risk can be 200%. There are also rapidly growing numbers of young people now seeking treatment for cannabis addiction. The Times recently headlined that in England: ?500 cannabis smokers a week seek medical help? (January 11th, 2008). Further, the effects of cannabis on the brain raise concerns that young people who use this drug may under-achieve in education or work. What we don?t yet understand is why some individuals can use cannabis with few apparent harmful effects whereas others become mentally ill or addicted or have problems concentrating and remembering. 

In the first research of its kind, we recently discovered that two main constituents (THC and CBD) in the cannabis that young people smoke influence the psychotic-like effects they experience in everyday life. The proposed research builds on this finding and on our recent large-scale study with 244 young people assessing the effects of cannabis. It aims to determine which cannabis-related and which individual factors make some young people vulnerable to the harmful effects of the drug. The three main harms it addresses are psychotic-like symptoms, addiction and cognitive impairment. The first phase of the study will be naturalistic and involve 600 16-23 year olds who differ in their cannabis use. Some cannabis users will be selected for Phase 2 - a controlled, laboratory study of the effects of two main constituents of cannabis (THC and CBD) both alone and combined. In both Phases, the effects we will assess are psychotic-like, addiction-related and cognitive. We will also investigate young people?s beliefs and views about different strains of cannabis, such as skunk and sinsemilla. 

At the time of writing this proposal, the Government is waiting for findings of yet another review of the classification of cannabis. Whether or not this results in it being raised from Class C to B will have negligible impact on cannabis users.

If we show that the harmful effects can be reduced if vulnerable youngsters choose strains with higher CBD content, or if they take CBD supplements, then this could lead to a new era of safer cannabis use. Importantly, it could significantly reduce the numbers of young people in the UK currently diagnosed schizophrenic who would not have become mentally ill if they had not used this drug.</gtr:abstractText><gtr:technicalSummary>The current debate on the harmful effects of cannabis centres mainly on psychosis but increasingly on addiction and cognitive impairment. A major unanswered question is: why are some individuals vulnerable and others resilient to these harmful effects? Our very recent finding suggests that one major constituent of cannabis ?cannabidiol (CBD)? protects against the harmful effects of THC, the drug?s main psychoactive constituent. The present research aims to determine how the CBD and THC content of cannabis interact with vulnerability factors - including an individual?s psychosis-proneness and level of cannabis use - to determine their acute response to this drug, a potential marker of longer-term harm. Phase I will be the first ever large-scale naturalistic study of the acute effects of cannabis and will involve 600 16-23 year olds: 200 daily and 200 recreational users, 100 ex-users and 100 non-using controls. Psychosis-like, dependence-related and cognitive effects will be assessed both whilst users are and are not intoxicated with the drug in a cross-over design. THC and CBD content of cannabis habitually taken will be measured in hair and that taken acutely will be measured in the ?spliff? actually smoked as well as saliva/urine levels. Relevant genetic markers will be assessed. Individuals? beliefs about and preferences for different strains of cannabis (e.g. skunk, hash) and intake behaviours (e.g. titration of dose) will also be explored. Phase II will employ the same psychotic-like, dependence-related and cognitive measures in a double-blind, balanced, placebo-controlled comparison of the acute effects of pure CBD and THC, both alone and in combination, in 48 cannabis users carefully selected from Phase I to differ in psychosis-proneness (high versus low) and extent of use (daily versus recreational). An intermediate phase of the study involves a semi-structured interview with subsets of 20 daily, recreational and ex-users to allow detailed exploraons for use, strains of cannabis used and response to information on risk factors (including personal feedback). If, as hypothesised, CBD protects against psychotic-like, cognitive and/or dependence-inducing effects of cannabis, this would have major implications for public health given that 40-50% of young British people use this drug. The potential use of CBD as a protective agent by vulnerable young people could significantly reduce the 14% who are currently diagnosed with a psychotic disorder in the UK who would not have been if they had not consumed cannabis. It could also impact clinically on prevention and treatment of cannabis dependence.</gtr:technicalSummary><gtr:fund><gtr:end>2012-03-12</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-10-13</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>580169</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Clinical Sciences Centre (CSC)</gtr:department><gtr:description>Sensitivity to acute effects of cannabis: PET and FMRI analysis</gtr:description><gtr:id>767723A2-1B70-4C2E-BFDB-EBECA717A84E</gtr:id><gtr:impact>There have been two publications (doi: 10.1007/s00213-014-3523-4 and 10.1016/j.biopsych.2013.05.027)</gtr:impact><gtr:outcomeId>JN5fJbQ2omN-1</gtr:outcomeId><gtr:partnerContribution>Brain scanning expertise and use of scanner</gtr:partnerContribution><gtr:piContribution>Recruitment of participants who are highly sensitive to acute cannabinoid psychotomimetic effects</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>IEPA Early Intervention in Mental Health (Milan, Italy)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>551C0A0F-F8EA-4495-A82F-AFFC4AF76324</gtr:id><gtr:impact>Talk by TF on 'Comparing different types of cannabis on cognition, reward and addiction' at Early Intervention in Mental Health International Conference in Milan, Italy, October 2016. Talk sparked questions and discussion afterwards.</gtr:impact><gtr:outcomeId>58bd74c82d0580.97996813</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Plenary lecture - Pembroke-King's Programme (PKP)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>CF9673E7-F8DB-495F-AAB0-CD7DC9D81955</gtr:id><gtr:impact>Talk sparked questions and discussion afterwards

N/A - public engagement activity</gtr:impact><gtr:outcomeId>546098cd8482d8.68371752</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Undergraduate students</gtr:primaryAudience><gtr:url>http://pembrokekings.wordpress.com/2014/07/21/pkp-plenary-lectures/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited speaker at The London Salon on Cannabis: Medicine, madness and Pleasure (London)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>7082B9E3-1AC0-4972-AF11-3BD429B3A19B</gtr:id><gtr:impact>Invited speaker at The London Salon to give talk on Cannabis: Medicine, madness and Pleasure. Talk sparked questions and discussion afterwards.</gtr:impact><gtr:outcomeId>56d70671a90238.72057346</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited speaker at 1st conference of the European Monitoring Centre for Drugs and Drug Addiction (Lisbon, Portugal)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>6303479F-7E72-4294-BAD0-732905CEB9D5</gtr:id><gtr:impact>Invited talk on Purple haze, Northern lightsneurocognitive effects of different strains of cannabis at 1st conference of the European Monitoring Centre for Drugs and Drug Addiction. Talk sparked questions and discussion afterwards</gtr:impact><gtr:outcomeId>56d705d7021235.86186092</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.lisbonaddictions.eu/start</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>UCL Institute of Mental Health Clinical Academic Seminar (London)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>30752254-AC97-45FB-98C0-70FD44F1250A</gtr:id><gtr:impact>Presentation by HVC at UCL Institute of Mental Health on Cannabis: pleasure, madness, medicine. Talk sparked questions and discussion afterwards.</gtr:impact><gtr:outcomeId>58bd5fc2356a40.73073488</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited speaker, American College of Neuropharmacology (ACNP), How does the THC and CBD content of cannabis influence its effects? (Miami, USA)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>274A63FF-EFFE-4B95-A8B7-4577824FAB3A</gtr:id><gtr:impact>Invited speaker at American College of Neuropharmacology (ACNP) annual meeting. 1700 members and scientific guests in attendance. 
Talk on How does the THC and CBD content of cannabis influence its effects?</gtr:impact><gtr:outcomeId>58bd5c3f38ce17.78732420</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.acnp.org/default.aspx</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Newcastle University (Newcastle, UK)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>D066FCD5-1B21-4C7D-B402-1528DDBF20D0</gtr:id><gtr:impact>Talk by HVC at Newcastle University on Cannabis: pleasure, madness, medicine. Talk sparked questions and discussion afterwards.</gtr:impact><gtr:outcomeId>58bd6e938ef060.21878502</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Article in Newsweek: How procedural and legal restrictions make studying the effects of medical marijuana difficult (2010)</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D2CAF2B4-B39D-4F65-8B53-CA669525F4CF</gtr:id><gtr:impact>Article was published in Newsweek as a result of publications from MRC grant

N/A</gtr:impact><gtr:outcomeId>sguy5wY8QvY</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>University College Hospital weekly Accident and Emergency meeting (UK)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>7DFFD9E5-24EE-4D8C-BBBC-59AC67A2A821</gtr:id><gtr:impact>Presentation by TF on 'Cannabidiol: a novel intervention for cannabis use problems?' University College Hospital weekly Accident and Emergency meeting, UK, June 2014. Talk sparked questions and discussion afterwards</gtr:impact><gtr:outcomeId>58bd767379b658.84989363</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ECNP Junior Scientist Workshop (Nice, France, March 2017)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>331ABD73-8636-4A87-932C-8AB7FDA721ED</gtr:id><gtr:impact>Talk by TF on 'Cannabis increases wanting but not liking of music and dampens its rewarding effects on the brain' ECNP Junior Scientist Workshop, Nice, France, March 2017. Talk sparked questions and discussion afterwards.</gtr:impact><gtr:outcomeId>58bd74068c46c9.66868837</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>TV documentary for SKY TV (2010)</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D297CE9B-8B11-482F-BD4D-F397454E9B74</gtr:id><gtr:impact>Documentary showing one of our cannabinoid experiments and discussing findings.

N/A</gtr:impact><gtr:outcomeId>Msddaz19Nds</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public lecture: The Intoxication Season at Kew Gardens - Cannabis: medicine or madness?</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>918FCF57-963A-4C05-9A44-1E5A9A71E2DB</gtr:id><gtr:impact>Talk sparked questions and discussion afterwards

Public engagement activity - talk sparked questions and discussion afterwards from members of the public and Kew staff who attended.</gtr:impact><gtr:outcomeId>546097cb01aa14.77229487</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.kew.org/visit-kew-gardens/whats-on/intoxication-season</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>A new approach to European drug policy for the 21st century</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>FDE52F14-B2FB-4E5F-B8FC-A2C5B98F3C46</gtr:id><gtr:impact>Talk sparked questions and discussions afterwards

Talk led to a visit to us in London by Madame Ruth Dreifuss (ex-President of Switzerland; member of the Global Drugs Commission)</gtr:impact><gtr:outcomeId>54609270be4978.52800310</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:url>https://www.youtube.com/watch?v=ldQ53v37Y8U&amp;feature=youtu.be</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Article in Nature News: Key ingredient staves off marijuana memory loss (2010)</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>22BD6E2C-0E5C-45F4-8301-9A172231E401</gtr:id><gtr:impact>Article was published in Nature News as a result of journal article in British Journal of Psychiatry.

Other media interest derived from this article on the front page of Nature News (eg article in Telegraph)</gtr:impact><gtr:outcomeId>gACAgyoEMk8</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Nature article (2012)</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>87D8B89A-F8DD-4F37-8837-86D90806C05B</gtr:id><gtr:impact>Response to published manuscript in Nature - 'Drop in IQ linked to heavy teenage cannabis use' in Nature magazine

N/A</gtr:impact><gtr:outcomeId>qYWDkdzQk3C</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Wellcome Trust 'High Society' exhibition (London, 2011)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>D6AA48F2-94CF-4EF2-B110-B8D450D2E9D5</gtr:id><gtr:impact>Public talk on 'What is a drug?' as part of Wellcome Trust 'High Society' exhibition

No notable impact as yet</gtr:impact><gtr:outcomeId>FC1UqyxZQ17</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Early Phase Clinical Trials Workshop, MRC Clinical Trials Unit (London, November 2015)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>A1851546-DD8A-4665-9E06-4F97A110EAAB</gtr:id><gtr:impact>Talk by TF on 'Risk evaluation: monitoring on a CBD trial' Early Phase Clinical Trials Workshop, MRC Clinical Trials Unit, London, November 2015. Talk sparked questions and discussion afterwards.</gtr:impact><gtr:outcomeId>58bd7579eaf7e4.90898345</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>University of Hertfordshire. Talk on Cannabis and cannabinoids: mental health and medicines (Hertfordshire )</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>1EE73AFF-A2F5-41D0-8EC2-B0AA6C38A8CA</gtr:id><gtr:impact>Presentation by HVC at University of Hertfordshire (16/02/2017) on Cannabis and cannabinoids: mental health and medicines. Talk sparked question and discussion afterwards</gtr:impact><gtr:outcomeId>58bd6cf3db5254.88062734</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>British Neuroscience Association (Edinburgh, Scotland)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>EABCAA27-81C9-400A-9DAE-0ADC40937975</gtr:id><gtr:impact>Presentation by TF on 'Cannabis and addiction: cause, cure or both?' British Neuroscience Association, Edinburgh, April 2015. Talk sparked questions and discussion afterwards.</gtr:impact><gtr:outcomeId>58bd763a07aa13.75038888</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>All Party Parliamentary Committee on Drug Policy Reform (House of Lords, London)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>BB28EB8B-D11B-4EC1-A1F1-D830C8D28C52</gtr:id><gtr:impact>All Party Parliamentary Committee on Drug Policy Reform, House of Lords, Feb 10th 2016. Talk on 'The case for rescheduling cannabis under the medicines act'</gtr:impact><gtr:outcomeId>58bd5dc9310c07.62030040</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public lecture - Cannabis: pleasure, madness &amp; medicine</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>2FD04AF0-53A0-49DD-88D2-C6C09F658A62</gtr:id><gtr:impact>Talk sparked questions and discussion afterwards

N/A - public engagement activity</gtr:impact><gtr:outcomeId>546094bd19e1d2.84843553</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.scienceandcocktails.org/2014/Cannabis.html</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>UCL Neuroscience Society (London)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>FD2A23A4-86FF-4B92-8BFE-A08D5A9C8D24</gtr:id><gtr:impact>Presentation by HVC at UCL Neuroscience Society on Cannabis: pleasure, medicine, madness. 18/10/2016. Talk sparked questions and discussion afterwards.</gtr:impact><gtr:outcomeId>58bd6d45bdb3a2.05338179</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Institute of Psychology Health and Society Departmental Seminar, University of Liverpool ( Liverpool, UK).</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>94248D69-AC65-4F53-9AE9-1B80D4E81E61</gtr:id><gtr:impact>Presentation by TF on 'Can we reduce the harmful effects of cannabis?' at the Institute of Psychology Health and Society Departmental Seminar, University of Liverpool, UK, May 2014. Talk sparked questions and discussion afterwards</gtr:impact><gtr:outcomeId>58bd76f7431ff5.24602826</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>British Association for Psychopharmacology Summer Meeting (Brighton, UK)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C40211C5-0A42-4AAA-AE99-F7762D422227</gtr:id><gtr:impact>Talk by TF on 'Dissociable effects of cannabinoids on anticipatory and consummatory reward processing' at British Association for Psychopharmacology Summer Meeting, Brighton UK, July 2016. Talk sparked questions and discussion afterwards.</gtr:impact><gtr:outcomeId>58bd751b7a7de6.85302792</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015,2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BBC Radio 4 PM - Talk on Cannabis and CBD trial (London)</gtr:description><gtr:form>A broadcast e.g. TV/radio/film/podcast (other than news/press)</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>0C89F533-FC3F-4D3D-ABD6-4495BAB5F824</gtr:id><gtr:impact>Prof. Val Curran and Dr Tom Freeman talk about cannabis and the CBD clinical trial as part of Cannabis week on BBC Radio 4. http://www.bbc.co.uk/programmes/b05s310m</gtr:impact><gtr:outcomeId>56dd5cd0bfc5f9.92665702</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.bbc.co.uk/news/science-environment-31518546</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BBC Three documentary How Drugs work Cannabis (2011)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>AD56F906-6363-4651-910E-95B995565EA1</gtr:id><gtr:impact>Documentary showing the effects of Cannabis and one of our cannabinoid experiments

N/A</gtr:impact><gtr:outcomeId>HigibYuELSe</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media interview - Cannabis: Promise, risk and controversy</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>23BC866E-2D90-4E6A-B407-44B87D2A237F</gtr:id><gtr:impact>Article on Cannabis: Promise, risk and controversy</gtr:impact><gtr:outcomeId>58c03485af6fb4.74800544</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.bbc.co.uk/news/science-environment-31518546</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>European Monitoring Centre for Drugs and Drug Addiction (Lisbon, Portugul)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>64C9A197-92A5-4E80-9FB0-7763636BD8FC</gtr:id><gtr:impact>Talk by TF on 'How can we optimise the treatment of people who are cannabis dependent?' European Monitoring Centre for Drugs and Drug Addiction (EMCDDA): Lisbon Addictions 2015.Talk sparked questions and discussion afterwards.</gtr:impact><gtr:outcomeId>58bd75e9683aa8.34244538</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>American Psychosomatic Society 74th Annual Scientific Meeting (Denver, Colorado)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>06B5EF2A-5FF3-4120-8130-EE303A67286A</gtr:id><gtr:impact>American Psychosomatic Society 74th Annual meeting in Denver, Colorado, USA. Plenary speaker on Cannabinoids and Cannabis Use Disorder. Talk sparked questions and discussion afterwards.</gtr:impact><gtr:outcomeId>58bd5d31d9ca71.25500693</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1042</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>European College of Neuropsychopharmacology Fellowship Award</gtr:description><gtr:end>2010-10-02</gtr:end><gtr:fundingOrg>European College of Neuropsychopharmacology (ECNP)</gtr:fundingOrg><gtr:id>5102108A-7BAF-4936-B2F1-8AFFE641D1A1</gtr:id><gtr:outcomeId>qiRKpN1c9ZB0</gtr:outcomeId><gtr:sector>Learned Society</gtr:sector><gtr:start>2009-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>British Medical Association Margaret Temple Grant - Developing an endocannabinoid clinical model of schizophrenia: a multimodal pharmacological imaging study</gtr:description><gtr:end>2017-12-02</gtr:end><gtr:fundingOrg>British Medical Association (BMA)</gtr:fundingOrg><gtr:id>FE9135A0-EACA-4F77-9838-6C584B083FD7</gtr:id><gtr:outcomeId>58c02f2bb91ba6.64932840</gtr:outcomeId><gtr:sector>Learned Society</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>45000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC studentship</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>E83CAEE8-D7FD-4B3B-9152-606E0DD6F157</gtr:id><gtr:outcomeId>g91brhivBCU1</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>10000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Beckley Foundation</gtr:description><gtr:end>2015-11-02</gtr:end><gtr:fundingOrg>Beckley Foundation</gtr:fundingOrg><gtr:id>1388033C-85AA-4E18-9834-3B45DE3ADFBE</gtr:id><gtr:outcomeId>54608fac9fd8a6.64235608</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>69710</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC ESRC Interdisciplinary Studentships</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>G0900207</gtr:fundingRef><gtr:id>E2B2CA69-7819-49DF-81F5-B0603DA97FCC</gtr:id><gtr:outcomeId>C294A6CEC3E0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Scientific expert - evidence to the All Parliamentary Committee at the House of Lords on Reform of Drug Policy (Baroness Meacher Chair)</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>59DA89F0-A06B-4CC7-8B17-4D8E2E58F11F</gtr:id><gtr:outcomeId>qvjLcaeB1wh</gtr:outcomeId><gtr:type>Gave evidence to a government review</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>All Party Parliamentary Committee on Drug Policy Reform, House of Lords, 'The case for rescheduling cannabis under the medicines act'</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>39A7D280-5C93-4EFC-AA12-16838B6304A9</gtr:id><gtr:outcomeId>56d7010ef301a6.54472307</gtr:outcomeId><gtr:type>Gave evidence to a government review</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>All Party Parliamentary Committee on Drug Policy Reform, House of Lords. 'The case for rescheduling cannabis under the medicines act'</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D58FB3A4-B48C-4516-ABCC-2731C5A0792B</gtr:id><gtr:outcomeId>58bd6f8d0dae40.24129154</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>DrugScience</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>84D413A7-55A3-4BE4-AE11-0FF1043D4DA8</gtr:id><gtr:outcomeId>dfLUEgqiHT6</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>FF2379F6-4AB1-4915-B9DD-6AC4C9F0BFAB</gtr:id><gtr:title>Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being.</gtr:title><gtr:parentPublicationTitle>Psychological medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/014e80c626f6bbc9f4b2ef77f7209d6d"><gtr:id>014e80c626f6bbc9f4b2ef77f7209d6d</gtr:id><gtr:otherNames>Morgan CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0033-2917</gtr:issn><gtr:outcomeId>nyHbTViff3S</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>24D7AB85-0E3E-4E28-AC0B-FC5FE26A36C3</gtr:id><gtr:title>Cannabidiol enhances consolidation of explicit fear extinction in humans.</gtr:title><gtr:parentPublicationTitle>Psychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/938e9e68e1c18dc4a46e50401bea049d"><gtr:id>938e9e68e1c18dc4a46e50401bea049d</gtr:id><gtr:otherNames>Das RK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0033-3158</gtr:issn><gtr:outcomeId>54608da7917b33.74446425</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4DEFFD54-210B-408C-B474-9C04E2002944</gtr:id><gtr:title>Neurocognitive function and schizophrenia-proneness in individuals dependent on ketamine, on high potency cannabis ('skunk') or on cocaine.</gtr:title><gtr:parentPublicationTitle>Pharmacopsychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/014e80c626f6bbc9f4b2ef77f7209d6d"><gtr:id>014e80c626f6bbc9f4b2ef77f7209d6d</gtr:id><gtr:otherNames>Morgan CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0176-3679</gtr:issn><gtr:outcomeId>pm_14515_25_22511328</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>06D355B0-A95F-4937-B676-6762D3428988</gtr:id><gtr:title>Cannabis potency: the need for global monitoring.</gtr:title><gtr:parentPublicationTitle>Addiction (Abingdon, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e4ad1a624540e3dfb13ba77aa179d8c"><gtr:id>8e4ad1a624540e3dfb13ba77aa179d8c</gtr:id><gtr:otherNames>Freeman TP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0965-2140</gtr:issn><gtr:outcomeId>58bd718c34c0c6.87402084</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AC89FC96-9C65-4CD8-B5F6-C99D6B9445D0</gtr:id><gtr:title>Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings.</gtr:title><gtr:parentPublicationTitle>Addictive behaviors</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/014e80c626f6bbc9f4b2ef77f7209d6d"><gtr:id>014e80c626f6bbc9f4b2ef77f7209d6d</gtr:id><gtr:otherNames>Morgan CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0306-4603</gtr:issn><gtr:outcomeId>pm_14515_25_23685330</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7E152B65-1EC4-4550-A44F-496F1B9D1A21</gtr:id><gtr:title>Just say 'know': how do cannabinoid concentrations influence users' estimates of cannabis potency and the amount they roll in joints?</gtr:title><gtr:parentPublicationTitle>Addiction (Abingdon, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e4ad1a624540e3dfb13ba77aa179d8c"><gtr:id>8e4ad1a624540e3dfb13ba77aa179d8c</gtr:id><gtr:otherNames>Freeman TP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0965-2140</gtr:issn><gtr:outcomeId>545a304ca0a675.18418963</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C5305E9A-13E1-4580-ADAA-EE048ABA1C3B</gtr:id><gtr:title>Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study: naturalistic study [corrected].</gtr:title><gtr:parentPublicationTitle>The British journal of psychiatry : the journal of mental science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/014e80c626f6bbc9f4b2ef77f7209d6d"><gtr:id>014e80c626f6bbc9f4b2ef77f7209d6d</gtr:id><gtr:otherNames>Morgan CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0007-1250</gtr:issn><gtr:outcomeId>RAyTvvKDLVa</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F575EC3D-AF14-4C25-BD1C-84576404343D</gtr:id><gtr:title>Rethinking dose-response effects of cannabis use in adolescence</gtr:title><gtr:parentPublicationTitle>The Lancet Psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9e9a0bba947702815a0f599ea1687ebc"><gtr:id>9e9a0bba947702815a0f599ea1687ebc</gtr:id><gtr:otherNames>Freeman T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>545a363d62c0a2.62099660</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5FB51ECE-2CC4-4AF3-A814-DDB8B60BF15E</gtr:id><gtr:title>Does cannabidiol protect against the negative effects of THC?</gtr:title><gtr:parentPublicationTitle>The British journal of psychiatry : the journal of mental science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d8f0f8c3fce20dafc6e06fdd6bfdca3c"><gtr:id>d8f0f8c3fce20dafc6e06fdd6bfdca3c</gtr:id><gtr:otherNames>Henquet C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0007-1250</gtr:issn><gtr:outcomeId>Wwir3mdXnRW</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5E598682-7146-4602-AD9D-A7240C610A7A</gtr:id><gtr:title>Examining the profile of high-potency cannabis and its association with severity of cannabis dependence.</gtr:title><gtr:parentPublicationTitle>Psychological medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e4ad1a624540e3dfb13ba77aa179d8c"><gtr:id>8e4ad1a624540e3dfb13ba77aa179d8c</gtr:id><gtr:otherNames>Freeman TP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0033-2917</gtr:issn><gtr:outcomeId>58bd718c82d937.94148292</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E0957A36-DF9C-4056-AFDB-B376077DEC3D</gtr:id><gtr:title>Investigating the interaction between schizotypy, divergent thinking and cannabis use.</gtr:title><gtr:parentPublicationTitle>Consciousness and cognition</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9b1e430ad7523355b5a2c0bca3352beb"><gtr:id>9b1e430ad7523355b5a2c0bca3352beb</gtr:id><gtr:otherNames>Schafer G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1053-8100</gtr:issn><gtr:outcomeId>pm_14515_25_22230356</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6F5F4FB7-7CD4-403F-AFA2-B99BA043CDA0</gtr:id><gtr:title>AKT1 genotype moderates the acute psychotomimetic effects of naturalistically smoked cannabis in young cannabis smokers.</gtr:title><gtr:parentPublicationTitle>Translational psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/014e80c626f6bbc9f4b2ef77f7209d6d"><gtr:id>014e80c626f6bbc9f4b2ef77f7209d6d</gtr:id><gtr:otherNames>Morgan CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2158-3188</gtr:issn><gtr:outcomeId>56d6ffd7afaf64.52242811</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D5ADD591-643E-451B-81A3-27B2FB216F4E</gtr:id><gtr:title>Processing dynamic facial affect in frequent cannabis-users: evidence of deficits in the speed of identifying emotional expressions.</gtr:title><gtr:parentPublicationTitle>Drug and alcohol dependence</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/409d6bc4f883d87fd128883adbe16e28"><gtr:id>409d6bc4f883d87fd128883adbe16e28</gtr:id><gtr:otherNames>Platt B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0376-8716</gtr:issn><gtr:outcomeId>pm_14515_25_21036306</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D4121089-CCAA-4F5C-AB14-3718A894DB43</gtr:id><gtr:title>Keep off the grass? Cannabis, cognition and addiction.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1a086a2eb787e9fe404d71084e9e0b7a"><gtr:id>1a086a2eb787e9fe404d71084e9e0b7a</gtr:id><gtr:otherNames>Curran HV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1471-003X</gtr:issn><gtr:outcomeId>58a47f4a723cd8.51624296</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EC93D10D-B059-4B0B-9CCC-A7A0FA9699D4</gtr:id><gtr:title>Salience attribution and its relationship to cannabis-induced psychotic symptoms.</gtr:title><gtr:parentPublicationTitle>Psychological medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/413ae84d0e24f0badbf8a45ff98faf7f"><gtr:id>413ae84d0e24f0badbf8a45ff98faf7f</gtr:id><gtr:otherNames>Bloomfield MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0033-2917</gtr:issn><gtr:outcomeId>58bfdd95ecca33.82454687</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B765DA87-3EBD-4A7F-80AC-60252169DA63</gtr:id><gtr:title>Acute and chronic effects of cannabinoids on effort-related decision-making and reward learning: an evaluation of the cannabis 'amotivational' hypotheses.</gtr:title><gtr:parentPublicationTitle>Psychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7bbf8dc457e44c6f97be70812536a66f"><gtr:id>7bbf8dc457e44c6f97be70812536a66f</gtr:id><gtr:otherNames>Lawn W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0033-3158</gtr:issn><gtr:outcomeId>58c01006d88012.89696543</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8824A7B3-2066-45C3-A817-E890564B8039</gtr:id><gtr:title>Emotional processing deficits in chronic cannabis use: a replication and extension.</gtr:title><gtr:parentPublicationTitle>Journal of psychopharmacology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0e214e19bbf02017e68d12e972df1e55"><gtr:id>0e214e19bbf02017e68d12e972df1e55</gtr:id><gtr:otherNames>Hindocha C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0269-8811</gtr:issn><gtr:outcomeId>545a304cec47c2.96015738</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6FA60D66-0BBF-4548-974A-E399F324C2AC</gtr:id><gtr:title>Cannabidiol attenuates the appetitive effects of Delta 9-tetrahydrocannabinol in humans smoking their chosen cannabis.</gtr:title><gtr:parentPublicationTitle>Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/014e80c626f6bbc9f4b2ef77f7209d6d"><gtr:id>014e80c626f6bbc9f4b2ef77f7209d6d</gtr:id><gtr:otherNames>Morgan CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0893-133X</gtr:issn><gtr:outcomeId>kSKQj3CfwSM</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DE69F78A-2D5D-45DC-BC5E-46318457F8A2</gtr:id><gtr:title>The link between dopamine function and apathy in cannabis users: an [18F]-DOPA PET imaging study.</gtr:title><gtr:parentPublicationTitle>Psychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/413ae84d0e24f0badbf8a45ff98faf7f"><gtr:id>413ae84d0e24f0badbf8a45ff98faf7f</gtr:id><gtr:otherNames>Bloomfield MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0033-3158</gtr:issn><gtr:outcomeId>545a304cc84437.80564484</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>89161DC4-40F2-4BC8-B8F0-EDF5E2B7272C</gtr:id><gtr:title>Dopaminergic function in cannabis users and its relationship to cannabis-induced psychotic symptoms.</gtr:title><gtr:parentPublicationTitle>Biological psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/413ae84d0e24f0badbf8a45ff98faf7f"><gtr:id>413ae84d0e24f0badbf8a45ff98faf7f</gtr:id><gtr:otherNames>Bloomfield MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-3223</gtr:issn><gtr:outcomeId>545a304d21a0a3.25410559</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0800268</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>3C193D18-12BD-4B15-8347-037BA623E0FF</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Mental Health</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>878A242A-6B84-462E-BEA5-346583F6CA54</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.2  Psychological and socioeconomic processes</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>